Condition: Psoriasis · Overweight or Obesity · Sponsor: Eli Lilly and Company
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Medical Dermatology Specialists | Phoenix, Arizona, United States | Recruiting |
| First OC Dermatology Research Inc | Fountain Valley, California, United States | Recruiting |
| Center For Dermatology Clinical Research, Inc. | Fremont, California, United States | Recruiting |
| Metropolis Dermatology | Los Angeles, California, United States | Recruiting |
| Northridge Clinical Trials | Northridge, California, United States | Recruiting |
| NeoClinical Research | Hialeah, Florida, United States | Recruiting |
| Skin Care Research | Hollywood, Florida, United States | Recruiting |
| Encore Medical Research | Hollywood, Florida, United States | Recruiting |
| MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research | Tampa, Florida, United States | Recruiting |
| TruDerm & TruSpa | Wellington, Florida, United States | Recruiting |
| Southeast Research Specialists | Douglasville, Georgia, United States | Recruiting |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis, Indiana, United States | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06857942